Jun 26, 2025, 13:45
Dr Sthanu Subramanian: Tenecteplase VS Alteplase – TNK Targets the Fibrin in Blood Clots More Effectively
Dr. Sthanu Subramanian shared a post on X:
“Tenecteplase (TNK) vs. Alteplase (tPA):
TNK targets the fibrin in blood clots more effectively.
This means it is less likely to activate the body’s natural clotting system elsewhere, potentially reducing the risk of bleeding complications.”
Read also Dr Sthanu Subramanian Highlights EMS Protocols for Managing Atrial Fibrillation.
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC